パートナーシップ
Advancing the future of extracellular vesicle therapeutics requires strong scientific and strategic collaboration.
At EVerMed, we partner with academia, industry, and capital leaders to translate EV discovery into clinical impact and build a sustainable ecosystem for next-generation medicine.
University partnerships are essential to our innovation engine. By working with leading academic researchers and clinical institutions, we deepen EV biology insights, validate new targets, and accelerate translational studies that connect early discovery to real patient needs.
Industry partnerships are key to delivering our therapies at global scale. Together with pharmaceutical, biotech, and strategic partners, we advance development, manufacturing, and commercialization so that EV-based medicines and related technologies can reach patients worldwide.
Extracellular vesicles (EVs) are emerging as a transformative therapeutic modality, characterized by their intrinsic multi-target biological activity and versatility in engineering.
At EVerMed, we pursue a dual mission: to advance high-impact EV-based pipelines addressing unmet medical needs, and to build the technological infrastructure necessary for scalable, industrialized EV therapeutics.
Our goal is to establish EV medicine as a major pharmaceutical platform of the future.
EVerMed is led by internationally recognized experts in extracellular vesicle biology, translational research, and pharmaceutical strategy.
Our team combines deep academic excellence with extensive industry experience in drug development and regenerative medicine.
This integrated leadership structure enables us to bridge fundamental science with clinical and commercial realization.
Examples of Inquiries